gutflix
GI learning, personalised

Summary

EXOCRINE PANCREATIC INSUFFICIENCY AND ADVANCED PANCREATIC CANCER - A NATIONAL REGISTRY ANALYSIS

Lukas Perkhofer

UEG Week Vienna 2024 | Poster

Pancreas

October 13, 2024

A registry-based analysis of over 100 advanced pancreatic cancer patients found that fecal Elastase-1 testing was rarely performed and pancreatic enzyme replacement therapy was used less frequently than the reported incidence of exocrine pancreatic insufficiency would suggest.

KEY POINTS

- In this real-world setting across several specialised centres, fecal Elastase-1 measurement was not done routinely and was carried out only in few cases.
- Frequency of pancreatic enzyme replacement therapy in advanced pancreatic cancer patients was below the reported incidence in the literature of exocrine pancreatic insufficiency in this cohort.
- Potential exocrine pancreatic insufficiency-associated symptoms were stated more frequently in advanced pancreatic cancer patients compared to other gastrointestinal cancers such as colon cancer.
- The authors conclude that awareness of exocrine pancreatic insufficiency in advanced pancreatic cancer appears underrepresented and further prospective evaluation is needed.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/75c79094-9111-11ef-b0b3-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.